The process of manufacturing Libmeldy involves blood stem cells being selected from the patient, a working copy of the ARSA gene inserted and the gene-corrected cells infused back into the patient.
To ensure consistency and quality of treatment, Libmeldy will be available via qualified treatment centres with adequate experience in haematopoietic stem cell transplantation and the management of leukodystrophies. (see above)
The qualified treatment centre has the required infrastructure, procedures and accreditations in place, which are:
If you have identified an MLD patient in your clinic, please contact your local Orchard Therapeutics representative or send an email to: